Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Study Shows Coaching To Patient Activation Levels Improves Disease Management Outcomes
People with chronic health conditions who receive coaching tailored to their level of health activation showed significant improvements in clinical outcomes, and experienced fewer hospitalizations and visits to the emergency room than those coached using traditional methods, according to a study published in the June issue of The American Journal of Managed Care.
generic viagra online
Hyperion Therapeutics Receives Special Protocol Assessment Approval From FDA For Pivotal Phase III Trial In Urea Cycle Disorders
Hyperion Therapeutics announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for the pivotal Phase III trial of investigational product HPN-100 (glycerol phenylbutyrate) in adults with urea cycle disorders (UCD). The SPA is a written agreement between the trial sponsor and the FDA regarding the design, endpoints, and planned statistical analysis of the Phase III trial to be used in support of a New Drug Application (NDA).
News of the day
Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, And BRAF Gene Mutations In Reflex Testing Service
Quest Diagnostics Incorporated (NYSE: DGX), the world"s leading cancer diagnostics company, today launched the EGFR Pathway test (KRAS with reflex to NRAS, BRAF), the first laboratory-developed test from a national commercial reference laboratory for comprehensively identifying, in a single reflex test offering, genetic mutations in the KRAS, NRAS and BRAFL genes. The test is designed to aid the identification of the roughly half of all metastatic colorectal cancer (mCRC) patients who, because of certain mutations of the epidermal growth factor receptor (EGFR) pathway, are believed to be unresponsive to anti-EGFR cancer therapies for mCRC. While some commercial laboratory tests for predicting anti-EGFR response analyze certain mutations of the KRAS and BRAF genes, such as codons 12 and 13 of KRAS, the Quest Diagnostics test detects mutations in codons 12, 13 and 61 of both the KRAS and NRAS genes and mutations in exons 11, 12, and 15 of the BRAF gene, in a sequential reflex manner.
Sexual Health

New Research Claims Cholesterol Drug Could Reduce Risk Of Amputations In People With Diabetes

People with diabetes who were prescribed the cholesterol-lowering drug fenofibrate reduced their risk of minor amputations by 36 per cent, according to new research. Researchers in Australia, Finland and New Zealand looked at almost 10,000 people aged between 50 and 75 with Type 2 diabetes. About half of them were given fenofibrate while the other half were given placebos. New discovery The study, first published in 2005, aimed to see if fenofibrate prevented heart disease, which it did not. But in this new analysis, experts found patients on fenofibrate had a 36 per cent lower risk of a first amputation than those on the placebo. The risk of minor amputations in people without large vessel arterial disease was nearly 50 per cent lower in the group taking fenofibrates, but the risk of a major amputation was not substantially different between the two groups. Taller people were also more likely to have amputations. Fenofibrates can cause side effects including abdominal pain, nausea, pancreas and lung problems. Leading research forward "This large trial suggests that the drug fenofibrate could play a role in the reduction of below-the-ankle amputations in people with Type 2 diabetes," said Dr Victoria King, Research Manager at Diabetes UK. "We know that approximately 100 people a week in the UK lose a toe, foot or lower limb due to diabetes. "Managing blood glucose levels by keeping them within acceptable limits can cut the risk of diabetes-related amputations, and trials like this one guide us towards further ways of reducing the risk of diabetes associated amputations." Diabetes UK


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009